CagriSema 5mg Dosage & Mixing Guide

What is CagriSema?

CagriSema is a fixed-dose combination of two research peptides: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It was developed by Novo Nordisk for research into weight management and metabolic regulation.

The combination pairs amylin-receptor agonism — which promotes satiety and slows gastric emptying — with GLP-1-receptor agonism, which suppresses appetite and stimulates glucose-dependent insulin secretion. Together these two complementary pathways produce a dual-pathway effect on food intake and body weight that neither component achieves alone. The individual components, cagrilintide and semaglutide, are also studied separately in their own right.

Like its GLP-1 component, CagriSema has an extended half-life that allows for once-weekly administration in research protocols.

Fixed-dose co-formulation: This vial contains BOTH cagrilintide and semaglutide in a 1:1 fixed ratio. The mg figure refers to the total/combined peptide content per research vial. All doses in the tables below refer to the combined formulation, not to either component individually.

Quick Reference

Reconstitution Guide

Materials Needed

• CagriSema 5mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.

2. Clean the vial stoppers — Wipe the CagriSema vial stopper and BAC water vial with alcohol swabs. Allow to dry completely.

3. Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water.

4. Add water to peptide vial — Insert the needle into the CagriSema vial and slowly inject the BAC water down the inside wall of the vial. Do not spray directly onto the powder.

5. Allow to dissolve — CagriSema may take 5-10 minutes to fully dissolve. Gently swirl occasionally — never shake vigorously.

6. Verify dissolution — The solution should be completely clear and colorless. If cloudy or particles remain, continue gentle swirling.

7. Label and store — Write the reconstitution date on the vial. Store in refrigerator immediately.

Dosage Protocol

Concentration Calculations

With 5mg combined peptide in 2mL BAC water:

• Concentration: 2.5mg/mL = 2500mcg/mL
• Per unit (U-100 syringe): 25mcg per unit

Common Dose Calculations

Doses in this table refer to the combined co-formulation, not to cagrilintide or semaglutide individually.

Suggested Titration Protocol

CagriSema research protocols typically employ gradual dose escalation to assess tolerance:

Important Notes:

• Each dose level should be maintained for at least 4 weeks before escalation
• Not all research protocols require reaching maximum dose
• Dose escalation should be based on research objectives and tolerance

Injection Guide

Subcutaneous Administration

1. Clean the injection site with an alcohol swab
2. Pinch a fold of skin (abdomen, thigh, or upper arm)
3. Insert needle at 90° angle for most body types
4. Inject slowly and steadily
5. Wait 5-10 seconds before withdrawing needle
6. Apply light pressure if needed — do not rub

Site Rotation

Rotate between these areas weekly:

• Abdomen (2+ inches from navel) — most common
• Outer thigh (front/outer area)
• Back of upper arm

Consistency tip: Administer on the same day each week to maintain steady levels.

Storage Requirements

Lyophilized (Powder Form)

• Temperature: -20°C (-4°F) or colder
• Duration: 2+ years
• Conditions: Protect from light and moisture

Reconstituted (Mixed with BAC Water)

• Temperature: 2-8°C (36-46°F) — standard refrigerator
• Duration: 4-6 weeks
• Conditions: Keep away from light, never freeze reconstituted solution

Important Storage Notes

• CagriSema is sensitive to temperature — minimize time outside refrigeration
• Do not use if solution becomes cloudy, discolored, or contains particles
• Keep track of reconstitution date and discard after 6 weeks maximum

Research Considerations

Mechanism of Action

CagriSema’s research applications stem from its dual amylin and GLP-1 receptor agonism:

• Amylin pathway (cagrilintide): Enhanced satiety, slowed gastric emptying
• GLP-1 pathway (semaglutide): Appetite suppression, glucose-dependent insulin secretion
• CNS effects: Complementary appetite regulation via central pathways
• Combined effect: Dual-pathway modulation of food intake and body weight

Key Research Findings

Clinical research (REDEFINE program, phase 2 trials) has demonstrated:

• Significant effects on body weight in metabolic research
• Improvements in glycemic parameters in type 2 diabetes research
• Complementary benefit from combining amylin and GLP-1 pathways

Safety & Handling

General Precautions

• Use sterile technique for all preparations
• Never reuse needles or syringes
• Dispose of sharps properly in designated containers
• Store away from children and unauthorized persons

Research Considerations

• CagriSema is for research purposes only
• CagriSema is an investigational research peptide combination, not an approved medicine
• Research-grade peptides are not equivalent to pharmaceutical preparations
• Follow institutional guidelines for peptide research

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. Frias JP, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in participants with type 2 diabetes: a phase 2 trial.” The Lancet. 2023.
2. Novo Nordisk REDEFINE clinical trial program (cagrilintide + semaglutide co-formulation) for weight management. 2024.

Last updated: July 04, 2026

Disclaimer: This information is for educational and research purposes only. CagriSema as a research peptide combination is not intended for human consumption. CagriSema is an investigational research peptide combination, not an approved medicine. Always follow applicable laws and institutional guidelines.